Markets & Finance

Merrill Cuts Pharmaceutical Resources to 'Neutral'


Merrill Lynch downgraded Pharmaceutical Resources (PRX) to neutral from buy.

Analyst Gregory Gilbert says ever since the drugmaker launched a generic version of antidepressant Paxil on Sept. 8, its stock is up about $11. While Gilbert thinks the upwards move may be justified, he also thinks the Street's estimates may be too low for 2003 and 2004 and he expects the stock to take a breather.

Gilbert has confidence that management will take advantage of this period of earnings and cash flow upside to improve the long-term growth potential -- maybe in the form of increased R&D spending and M&A activity. He sees $3.34 2003 earnings per share (GAAP), and $3.66 for 2004. Additionally, he notes Pharmaceutical Resources could deliver results well ahead of estimates if no other generic companies launch generic Paxil in the coming quarters.


American Apparel's Future
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

 
blog comments powered by Disqus